Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

INOVIQ LTD Capital/Financing Update 2019

Jun 13, 2019

65112_rns_2019-06-13_58d302b6-5f0b-4db7-bdbc-67aa962220b9.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Market Announcement

==> picture [33 x 50] intentionally omitted <==

14 June 2019

==> picture [451 x 5] intentionally omitted <==

Bard1 Life Sciences Limited (ASX: BD1) – Trading Halt

Description

The securities of Bard1 Life Sciences Limited (‘BD1’) will be placed in trading halt at the request of BD1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 18 June 2019 or when the announcement is released to the market.

Issued by

Anjuli Sinniah

Senior Adviser, Listings Compliance (Perth)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

14 June 2019 ASX Limited

==> picture [155 x 50] intentionally omitted <==

14 June 2019

The Manager Australian Securities Exchange 152-158 St Georges Terrace PERTH WA 6000

REQUEST FOR A TRADING HALT

Pursuant to ASX Listing Rule 17.1, BARD1 LIFE SCIENCES LIMITED ( ASX:BD1 ) ( Company ) requests a trading halt of its securities from ASX with effect from commencement of trading on 14 June 2019.

In accordance with ASX Listing Rule 17.1, the Company provides the following information regarding this request:

  1. The Company is requesting the trading halt pending an announcement to the market regarding a potential equity raising.

  2. The Company requests that the trading halt continue until the earlier of commencement of trading on 18 June 2019, being the second trading day after the trading halt commenced, or when the capital raising referred to in paragraph 1 above is announced to ASX.

  3. The Company is not aware of any reason why the trading halt should not be granted and is not aware of any other information necessary to inform the market about the trading halt.

Pauline Collinson Company Secretary BARD1 Life Sciences Limited

BARD1 Life Sciences Limited (ABN 58 009 070 384) Headquarters | Harry Perkins Institute, L2/QQ Block, 6 Verdun St, Nedlands WA 6009, Australia Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E [email protected] | W www.bard1.com